A study exploring the safety and efficacy of Atezolizumab in combination with Obinutuzumab or Rituximab anti-CD20 therapy in participants with Relapse/Refractory Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL) and Waldenström Macrobulinemia (WM)

Cancer

Results
Download
Print

Study results

LPS MO39107 TeGAR Final Results December 2022 English (PDF, 0.5 MB)

LPS MO39107 TeGAR Final Results December 2022 Spanish (PDF, 1.0 MB)

LPS MO39107 TeGAR Final Results December 2022 Latvian (PDF, 0.9 MB)

LPS MO39107 TeGAR Final Results December 2022 Slovak (PDF, 0.5 MB)

LPS MO39107 TeGAR Final Results December 2022 German (PDF, 0.3 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A study exploring the safety and efficacy of Atezolizumab in combination with Obinutuzumab or Rituximab anti-CD20 therapy in participants with Relapse/Refractory Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL) and Waldenström Macrobulinemia (WM)

Study results

LPS MO39107 TeGAR Final Results December 2022 English (PDF, 0.5 MB)

LPS MO39107 TeGAR Final Results December 2022 Spanish (PDF, 1.0 MB)

LPS MO39107 TeGAR Final Results December 2022 Latvian (PDF, 0.9 MB)

LPS MO39107 TeGAR Final Results December 2022 Slovak (PDF, 0.5 MB)

LPS MO39107 TeGAR Final Results December 2022 German (PDF, 0.3 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

Directly contact Roche for questions

Contact the hospital directly

Thank you

Something went wrong

Request a call back

Find participating medical centers and current study status in each of them

A study exploring the safety and efficacy of Atezolizumab in combination with Obinutuzumab or Rituximab anti-CD20 therapy in participants with Relapse/Refractory Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL) and Waldenström Macrobulinemia (WM)

For the latest version of this information please go to www.forpatients.roche.com